IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis Confirmation No.: 1866

Serial No.: 10/699,110 Art Unit: 1612

Filed: October 30, 2003 Examiner: Fay, Zohreh A.

For: METHODS FOR THE Attorney Docket No: 9516-083-999
TREATMENT AND CAM: 501872-999082

MANAGEMENT OF

MACULAR DEGENERATION USING CYCLOPROPYL-N-{2-1(15)-1-(3-FTHOXY-4-

[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-

(METHYLSULFONYL)ETHYL]-

3-OXOISOINDOLINE-4-YL}CARBOXAMIDE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to Applicant's duty of disclosure under 37 C.F.R. § 1.56, enclosed is a list references for the Examiner's review and consideration. The references are listed on the enclosed "List of References Cited by Applicant." Copies of reference B01-B03 and C01-C07 are submitted herewith. Identification of the foregoing reference is not to be construed as an admission of Applicant or Attorneys for Applicant that such reference is available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the reference and make it of record by completing and returning the enclosed List of References.

No fee is believed due for the submission of this statement since it is being submitted before the mailing of a first Office action after the filing of a request for continued examination. However, if any fees are required, the Director is authorized to charge such fees to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: February 1, 2010 /Robert Chang/
Robert Chang Reg. No.: 63,753

for: Anthony M. Insogna Reg. No.: 35,203

JONES DAY 222 East 41st Street New York, NY 10017 (858) 314-1200